Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sells 33,353 Shares of Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYXGet Rating) Director William Richard White sold 33,353 shares of the stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $35.10, for a total transaction of $1,170,690.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ventyx Biosciences Price Performance

NASDAQ:VTYX opened at $36.71 on Wednesday. Ventyx Biosciences, Inc. has a twelve month low of $9.50 and a twelve month high of $41.29. The company’s 50 day moving average is $30.78 and its two-hundred day moving average is $27.21.

Ventyx Biosciences (NASDAQ:VTYXGet Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.14). As a group, research analysts forecast that Ventyx Biosciences, Inc. will post -1.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VTYX has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on shares of Ventyx Biosciences in a research report on Thursday, November 17th. They set an “overweight” rating and a $45.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Ventyx Biosciences in a research note on Monday, December 19th. They set a “buy” rating and a $50.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Buy” and a consensus price target of $49.50.

Institutional Trading of Ventyx Biosciences

Several large investors have recently bought and sold shares of VTYX. Bank of New York Mellon Corp grew its position in Ventyx Biosciences by 38.1% during the 1st quarter. Bank of New York Mellon Corp now owns 24,242 shares of the company’s stock worth $329,000 after purchasing an additional 6,688 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ventyx Biosciences by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 73,803 shares of the company’s stock valued at $1,002,000 after acquiring an additional 2,482 shares during the last quarter. State Street Corp boosted its holdings in shares of Ventyx Biosciences by 65.2% in the 1st quarter. State Street Corp now owns 171,195 shares of the company’s stock valued at $2,323,000 after acquiring an additional 67,590 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at $231,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Ventyx Biosciences by 57.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 11,984 shares of the company’s stock valued at $147,000 after acquiring an additional 4,391 shares during the last quarter. Hedge funds and other institutional investors own 95.57% of the company’s stock.

Ventyx Biosciences Company Profile

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Read More

Insider Buying and Selling by Quarter for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.